Cell2Cure
  • Home
  • The Company
  • Research, Technology and IP
  • Clinical
  • Investor and Partners
  • Publications
  • News
  • Careers
  • Contact us
Select Page

Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)

by Backoffice | Feb 9, 2023 | Studies and testing

The first patient with diabetic foot ulcer was treated with Cell2Cure’s allogeneic adipose tissue-derived mesenchymal stromal cell product (C2C_ASCs) January 24, 2023 at Bispebjerg University Hospital, Copenhagen, Denmark. The STEMFOOT study is carried out in...

Recent Posts

  • QC Scientist; Scientist for control of cell products
  • Endeavour Cells investment in Cell2Cure
  • Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases
  • Cell2Cure has treated the first patients with autism spectrum disorders and signs of leaky gut syndrome in a Phase I study
  • The Cell2Cure core technology has been granted patent rights in Canada

Archives

  • March 2025
  • January 2024
  • November 2023
  • October 2023
  • May 2023
  • April 2023
  • February 2023
  • November 2022
  • September 2022
  • August 2022
  • June 2022
  • April 2022
  • February 2022
  • July 2021
  • February 2021
  • January 2021
  • November 2020
  • October 2020
  • January 2020

Categories

  • Careers
  • Collaborations
  • Patents
  • Studies and testing
  • Trial results
© 2021 Cell2Cure | CVR.no 39401975 | Designed by ICR-Design ApS